ClinicalTrials.gg
CompletedNCT04515927Updated Jul 24, 2024

To Evaluate the Efficacy and Safety of JS002 in HoFH Patients

A Phase 2 interventional study of JS002 in Hyperlipemia, sponsored by Shanghai Junshi Bioscience Co., Ltd.. Completed at 1 site in China. Open to participants aged 12 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-07-24.

Sponsored by Shanghai Junshi Bioscience Co., Ltd. · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
31
Allocation
Not applicable
Ages
12 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 96 studies in Hyperlipidemias with a site in China — 31 open to participants now, 39 under way, 7 of them phase 3. Hyperlipidemias · China.

Enrollment
73rd of 80
31 · median 155
Started
2020
with 8 others
Phase 2
11 of 96
3 open now
Registered
25th of 96
by date
Lead sponsor
5 of 96
Shanghai Junshi Bioscience Co., Ltd.

Among the 96 studies in Hyperlipidemias with a site in China, this one is the 73rd largest by enrollment of the 80 interventional ones that give a count, is one of 9 that started in 2020, is one of 11 in phase 2, and was the 25th registered.

Hyperlipidemias

864 studies on the registry are indexed under Hyperlipidemias; 110 are open to participants now.

Browse Hyperlipidemias studies →

Open to participants now

31 of the 96 studies in Hyperlipidemias with a site in China are open now. Recruiting first, the newest first:

26 more — sign in →

All 31 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 66 Hyperlipidemias studies recruiting now, 26 (39%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.

This study: 12 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 96 studies in Hyperlipidemias with a site in China, or all of them as a file.
02

Study summary

JS002 is a recombinant human anti-PCSK9 monoclonal antibody. This phase II open-label, single-arm study aims to evaluate the efficacy and safety of JS002 in patients with homozygous familial hypercholesterolemia A dose group (450 mg) was set up in this study.Thirty subjects are planned to be enrolled.

Each subject required a maximum of 6 weeks of screening, 52 weeks of treatment, and 8 weeks of follow-up.

03

Conditions studied

  • Hyperlipemia

Browse trials for

04

Who can participate

Ages eligible
12 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed .
  2. Age ≥12 and ≤75 years old;
  3. Weight ≥40kg at the time of screening
  4. Patients diagnosed with HoFH
  5. Low-density lipoprotein cholesterol (LDL-C) level ≥3.4mmol/L at the time of screening
  6. Fasting triglycerides ≤4.5 mmol/L;

Exclusion criteria

Exclusion Criteria:

  1. History of class III-IV heart failure or EF\<30%
  2. History of uncontrolled arrhythmia within 3 months
  3. History of MI,UA, PCI or CABG, stroke within 3 months.
  4. History of DVT or pulmonary embolism within 3 months.
  5. Planned cardiac surgery or revascularization.
  6. Uncontrolled hypertension.
  7. Uncontrolled diabetes mellitius (>8.0%).
  8. Other conditions that the researchers considered inappropriate to participate in the study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    subcutaneous injection of JS002, 450mg, Q4W, 3/13 times.

    Drug: JS002

Interventions

06

What researchers measure

Primary outcomes

  1. The primary endpoint of effectiveness

    Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12

    Time frame: JS002 is administered subcutaneously every 4 weeks, from 12 or 52 weeks after initial administration

07

Study locations

1 site
  • Beijing Anzhen Hospital Capital Medical University
    Beijing, Beijing, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2020 to primary completion in May 2022, 20 months.

Of 30 phase 2 interventional studies under Hyperlipidemias, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 27. This study's 20 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2020
First posted
Aug 17, 2020
StartActual
Aug 17, 2020
Primary completionActual
May 6, 2022
CompletionActual
Jul 29, 2022
Last update
Jul 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04515927
Responsible party
Sponsor
First posted
Aug 17, 2020
Start date
Aug 17, 2020
Primary completion
May 6, 2022
Completion
Jul 29, 2022
Last update
Jul 24, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ongericimab

Start the discussion